Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan adjunctive therapy with inhaled nitric oxide for persistent pulmonary hypertension of the newborn
NL-OMON35761Phase 3Withdrawn
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in persistent pulmonary hypertension of the newborn (PPHN) comparing Bosentan + inhaled nitric oxide with Placebo + inhaled nitric oxide (2 arms). Planned start Aug 2011; status: withdrawn.
02
Drugs
bosentan
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on NL-OMON35761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35761.